Immune thrombocytopenia in adults
Sven Ekström
Clonal hematopoiesis: clinical relevance
Krisztina Varga
Primary CNS lymphoma
Mihai Ionescu
Quadruplet induction for newly diagnosed myeloma
Andrew Thompson
Bleeding, thrombosis and platelets: emerging therapies
Ece Şimşek
Hematopoiesis and stem cell biology: first-line treatment
Tiago Oliveira
Lymphoma: diagnosis and risk assessment
Jessica Turner
Myeloma and plasma cell disorders: emerging therapies
Nicole Parker
Bleeding, thrombosis and platelets: diagnosis and risk assessment
Daniel Brown
Hematopoiesis and stem cell biology: diagnosis and risk assessment
Hyun-woo Kim
Lymphoma: managing relapse
Jing Wang
Myeloma and plasma cell disorders: emerging therapies
Ulrike Meier
Zelvudocel plus tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive ALL: randomized phase 3 results of the SUMMIT-7 trial
Georgia Oikonomou
Ph-like signatures predicts outcome in T-cell ALL
Dana Ben-David
Ravotuzumab vedotin versus venetoclax and azacitidine in adults with newly diagnosed AML receiving intensive induction (ZENITH-3): a phase 2 trial
Alexandre David
Abelorimab versus direct oral anticoagulants in hemophilia B (CORONA-4): a phase 2 trial
Layla Hassan
Prognostic value of platelet response in people with severe hemophilia A: results from TRIDENT-7
Neta Katz
Treatment patterns and survival in relapsed CLL after covalent BTK inhibitors: real-world data from the multinational CLL registry
Ana Muñoz
Health-related quality of life in T-cell ALL: a prospective german study
Maya Cohen
Ph-like signatures predicts outcome in T-cell ALL
Raúl Vázquez
Multi-omic characterization of metabolic rewiring under BCL-2 inhibition in newly diagnosed AML patients ineligible for intensive chemotherapy
Daan van Dijk
Marsatimab versus emicizumab prophylaxis in people with severe hemophilia A (BEACON-5): a phase 1 trial
Mark Thompson
D-dimer predicts outcome in people with severe hemophilia A
Akiko Nakamura
Treatment patterns and survival in fit patients with untreated CLL: real-world data from the French CLL registry
Lei Zhu
Mrd negativity after induction predicts outcome in children with high-risk B-cell ALL
Jun Yang
Ph-like signatures predicts outcome in T-cell ALL
Wouter Bos
Quelcitamab plus cytarabine and daunorubicin in adults with newly diagnosed AML receiving intensive induction: phase 2 results of the TRIDENT-1 trial
Álvaro Martínez
Targeting platelet desialylation in bleeding and thrombotic disorders: preclinical evidence
Alice Davies
Efficacy and safety of efactocog beta in people with severe hemophilia A: primary analysis of the phase 3 ATLAS-1 study
Alexander Harris
Efficacy and safety of tovaclax in relapsed CLL after covalent BTK inhibitors: primary analysis of the phase 2 SAGA-6 study
Sophie Cooper
Long-term outcomes of relapsed B-cell precursor ALL treated with tyrosine kinase inhibitors: a international registry study of 146 patients
Eva Lehmann
Efficacy and safety of zelvudocel in T-cell ALL: primary analysis of the randomized phase 2 ALTITUDE-1 study
Markus Bauer
Prognostic value of FLT3-ITD allelic ratio in older adults with secondary AML: results from TRIDENT-9
Lucie Bernard
Efactocog beta plus low-molecular-weight heparin in adults with immune thrombocytopenia: phase 2 results of the ATLAS-6 trial
Mette Andersen
Treatment patterns and survival in cancer-associated venous thromboembolism: real-world data from the Italian hemostasis registry
Johannes Schwarz
Long-term outcomes of older patients with CLL and comorbidities treated with venetoclax and obinutuzumab: a multinational registry study of 812 patients
Alessandro Mariani
Real-world effectiveness of ponavatinib in adults with Philadelphia chromosome-positive ALL: a multicenter european cohort
Chloé Thomas
Targeting lineage switch after CD19-directed therapy in acute lymphoblastic leukemia (ALL): preclinical evidence
Bruno Silva
Efficacy and safety of ravotuzumab vedotin in older adults with secondary AML: primary analysis of the phase 3 VIKING-5 study
David King
Real-world effectiveness of rilvabrutinib in adults with immune thrombocytopenia: a multicenter spanish cohort
Sarah Schulz
Tovaclax versus venetoclax and obinutuzumab in CLL with del(17p) or TP53 mutation (CORONA-3): a phase 1b/2 trial
Elena Matei
Long-term outcomes of fit patients with untreated CLL treated with acalabrutinib: a French registry study of 304 patients
Helena Olsson
Efficacy and safety of corvalimab in children with high-risk B-cell ALL: primary analysis of the randomized phase 2 HELIOS-8 study
Camilla Jørgensen
Real-world effectiveness of corvalimab in relapsed B-cell precursor ALL: a multicenter spanish cohort
Lei Sun
Efficacy and safety of quelcitamab in NPM1-mutated AML: primary analysis of the randomized phase 2 SUMMIT-9 study
Stefan Scholz
Long-term outcomes of patients with antiphospholipid syndrome treated with direct oral anticoagulants: a international registry study of 231 patients
Emil Jonsson
Long-term outcomes of older patients with CLL and comorbidities treated with ibrutinib: a Nordic registry study of 812 patients
Juan Chen
Efficacy and safety of nelbrutinib in older patients with CLL and comorbidities: primary analysis of the phase 3 ECLIPSE-1 study
Nuria Rubio
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Divya Nair, Sébastien Garnier, Uri Rosenberg
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Bin Zhang, Seo-jun Yoon, Frida Sandberg
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Katherine Roberts, Johanna Peters, Emre Demir
New oral therapies for thalassemia
John Lewis
Treatment-free remission in CML: who, when and how
Sébastien Garnier
Ph-positive ALL without chemotherapy
Luca Vitale
Thrombosis prevention in MPN
Brian Edwards
Red cell disorders and hemoglobinopathies: long-term follow-up
Julien Lefebvre
Chronic myeloid leukemia: managing relapse
Óscar Hernández
Acute lymphoblastic leukemia: controversies and case discussion
Hélène Vincent
Myeloproliferative neoplasms: controversies and case discussion
Clara Vázquez
Red cell disorders and hemoglobinopathies: long-term follow-up
Katherine Johnson
Chronic myeloid leukemia: first-line treatment
Federico Barbieri
Acute lymphoblastic leukemia: managing relapse
Solveig Solberg
Myeloproliferative neoplasms: managing relapse
Ana Costa
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Karin van Dijk
Plenary lecture: Clonal hematopoiesis, aging and disease
Rocío Navarro